More than 25% of heart attack patients experience ongoing chest pain or heart failure in the year following successful interventions. The culprit is often microvascular obstruction (MVO), which occurs when small blood vessels become blocked, leading to the death of heart muscle. MVO can go undetected and untreated during the initial procedure, even though it's the most powerful prognostic indicator for future adverse outcomes. For every 1% increase in MVO, there's a corresponding 14% increase in one-year mortality risk and 8% increase in hospitalization due to heart failure.

CorFlow's CoFI system was designed by interventional cardiologists to enable the rapid detection and treatment of MVO while patients are in the catheter laboratory, also offering the ability to safely deliver therapeutic agents directly into the microvasculature. CoFI seamlessly fits into standard workflows as well using existing guide catheter and wire access, minimizing the additional procedural time.

CorFlow's CoFI system has earned the coveted U.S. Food and Drug Administration Breakthrough Designation for medical devices that provide more effective treatment of potentially life-threatening or irreversible conditions or diseases.